Berzosertib
- Generic Name
- Berzosertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25N5O3S
- CAS Number
- 1232416-25-9
- Unique Ingredient Identifier
- L423PRV3V3
- Background
Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
- Conditions
- Metastatic Lung Non-Small Cell CarcinomaMetastatic Lung Small Cell CarcinomaMetastatic Lung Neuroendocrine NeoplasmStage IVB Lung Cancer AJCC v8Metastatic Malignant Neoplasm in the BrainStage IVA Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
- Interventions
- Drug: BerzosertibOther: Quality-of-Life AssessmentProcedure: Therapeutic Conventional SurgeryRadiation: Whole-Brain Radiotherapy
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT02589522
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
- Conditions
- Head and Neck Carcinoma of Unknown PrimaryStage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Head and Neck Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Interventions
- Drug: BerzosertibDrug: CisplatinProcedure: Computed TomographyOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyRadiation: Radiation Therapy
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT02567422
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
- Conditions
- Stage IV Bladder Urothelial Carcinoma AJCC v7Metastatic Renal Pelvis and Ureter Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Ureter Urothelial Carcinoma
- Interventions
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 87
- Registration Number
- NCT02567409
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.